Form 4 for IDXX Idexx Laboratories
Accepted 2021-08-31 00:00:00 ET · period of report 2021-08-27 · accession 0001567619-21-016516 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-31 | 2021-08-27+ | IDXX | Turner Kathy V | SVP | M - OptEx | $77.87 | +2,526 | 5,125 | +97% | +$196.7K |
| DM | 2021-08-31 | 2021-08-27+ | IDXX | Turner Kathy V | SVP | S - Sale+OE | $686.21 | -2,526 | 2,875 | -47% | -$1.73M |
| DM | 2021-08-31 | 2021-08-27+ | IDXX | Turner Kathy V | SVP | M - OptEx | — | -2,526 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-27 | M | A | 276 | $64.24 | 3,151.39 | D | — | — | (F1) Includes a total of 9.3869 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2021. |
| 2 | Common | Common Stock | 2021-08-27 | S | D | 276 | $678.00 | 2,875.39 | D | — | — | |
| 3 | Common | Common Stock | 2021-08-30 | M | A | 2,250 | $79.54 | 5,125.39 | D | — | — | |
| 4 | Common | Common Stock | 2021-08-30 | S | D | 1,000 | $685.00 | 4,125.39 | D | — | — | |
| 5 | Common | Common Stock | 2021-08-30 | S | D | 1,250 | $689.00 | 2,875.39 | D | — | — | |
| 6 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2021-08-30 | M | D | 2,250 | — | 7,736 | D | $79.54 · — to 2025-05-13 | 2,250 Common Stock | (F5) Not applicable. (F4) Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| 7 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2021-08-27 | M | D | 276 | — | 0 | D | $64.24 · — to 2024-05-31 | 276 Common Stock | (F5) Not applicable. (F3) Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 138 shares in five annual installments beginning June 1, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |